Document Detail


Immunological effects and tolerability of a new fast updosed immunologically enhanced subcutaneous immunotherapy formulation with optimized allergen/adjuvant ratio.
MedLine Citation:
PMID:  22385366     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
BACKGROUND: Subcutaneous immunotherapy (SCIT) traditionally includes an updosing phase injecting increasing doses of allergen over a period of several weeks, followed by a maintenance phase. To establish shorter and more convenient updosing schedules, a fast updosed immunologically enhanced SCIT formulation has been developed by optimizing the allergen/adjuvant (aluminium hydroxide) ratio. METHODS: In a randomized, controlled, parallel-group trial, patients with grass pollen induced rhinoconjunctivitis with/without asthma were treated with an immunologically enhanced SCIT formulation (AVANZ, ALK, Denmark). The trial included updosing with five injections (300, 600, 3000, 6000 and 15 000 SQ+) injected either in weekly interval (Group 1) or in 3-4 days interval (Group 2) followed by two maintenance injections (15 000 SQ+), approximately 10 weeks treatment. The immunological effects (primary endpoint) and tolerability (secondary endpoint) of the updosing schedules were evaluated. RESULTS: Four hundred patients were treated (Group 1: 201, Group 2: 199). In both groups, an immunological response with statistically significant increases in levels of IgE-blocking factor, IgG(4) and IgE (P < 0.001), was induced from baseline to end of trial. Most frequently reported adverse events were local injection site reactions such as injection site swellings (Group 1: 30% of patients, Group 2: 41% of patients). Other frequently reported adverse events included systemic reactions (Group 1: 21% of patients, Group 2: 33% of patients), primarily mild to moderate allergic rhinitis and urticaria. CONCLUSIONS: Fast updosed immunologically enhanced SCIT with an optimized allergen/adjuvant ratio induced significant immunological effects and had an acceptable safety profile. Clinical efficacy will be investigated in future clinical trials.
Authors:
O Pfaar; K Jung; H Wolf; E Decot; J Kleine-Tebbe; L Klimek; E Wüstenberg
Related Documents :
22310746 - Modified transurethral incision for primary bladder neck obstruction in women: a method...
8444406 - Acute transverse myelopathy in multiple sclerosis: clinical and laboratory analyses.
15453106 - Twenty-year course of schizophrenia: the madras longitudinal study.
19542476 - Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conver...
20550666 - Bacteriological and cytological findings during the late puerperal period after two dif...
9167766 - Anemia associated with advanced prostatic adenocarcinoma: effects of recombinant human ...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-3-3
Journal Detail:
Title:  Allergy     Volume:  -     ISSN:  1398-9995     ISO Abbreviation:  -     Publication Date:  2012 Mar 
Date Detail:
Created Date:  2012-3-5     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7804028     Medline TA:  Allergy     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
© 2012 John Wiley & Sons A/S.
Affiliation:
Department of Otorhinolaryngology, Head and Neck Surgery, Center for Rhinology and Allergology Wiesbaden, University Hospital Mannheim, Mannheim, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Restricted photochemistry in the molecular solid state: structural changes on photoexcitation of Cu(...
Next Document:  Genotypic and phenotypic characterization of Staphylococcus epidermidis causing chronic relapsing pr...